[1]赵东慧,王 楠,杨思远.不同阿替普酶溶栓时间对急性缺血性脑卒中患者神经功能及不良反应的影响[J].医学信息,2023,36(14):108-111.[doi:10.3969/j.issn.1006-1959.2023.14.021]
　ZHAO Dong-hui,WANG Nan,YANG Si-yuan.Effect of Different Alteplase Thrombolysis Time on Neurological Function and Adverse Reactions in Patients with Acute Ischemic Stroke[J].Journal of Medical Information,2023,36(14):108-111.[doi:10.3969/j.issn.1006-1959.2023.14.021]
点击复制

不同阿替普酶溶栓时间对急性缺血性脑卒中患者神经功能及不良反应的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年14期
页码:
108-111
栏目:
论著
出版日期:
2023-07-15

文章信息/Info

Title:
Effect of Different Alteplase Thrombolysis Time on Neurological Function and Adverse Reactions in Patients with Acute Ischemic Stroke
文章编号:
1006-1959（2023）14-0108-04
作者:
赵东慧; 王 楠; 杨思远
（佳木斯市中心医院神经内二科，黑龙江 佳木斯 154002）
Author(s):
ZHAO Dong-hui; WANG Nan; YANG Si-yuan
(The Second Department of Neurology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China)
关键词:
急性缺血性脑卒中; 阿替普酶; 溶栓时间; 神经功能
Keywords:
Acute ischemic stroke; Alteplase; Thrombolysis time; Neurological function
分类号:
R743.3
DOI:
10.3969/j.issn.1006-1959.2023.14.021
文献标志码:
A
摘要:
目的 研究不同阿替普酶溶栓时间对急性缺血性脑卒中（AIS）患者神经功能及不良反应的影响。方法 选取2019年1月-2022年1月佳木斯市中心医院收治的90例AIS患者，按照随机数字表法分为A组（45例）和B组（45例），两组均给予阿替普酶静脉溶栓治疗，A组溶栓治疗时间为发病3 h内，B组溶栓治疗时间为发病3~4.5 h内，比较两组神经功能[美国卫生部卒中评分（NHISS）、中国脑卒中患者临床神经功能缺损程度评分量表（CSS）评分]、凝血指标[凝血酶原时间（PT）、活化部分凝血活酶时间（APTT）、凝血酶时间（TT）]、氧化与炎症反应指标[丙二醛（MDA）、白细胞介素-1β（IL-1β）、肿瘤坏死因子-α（TNF-α）]、不良反应、预后情况[改良Rankin量表（mRS）、改良Barthel指数（MBI）]。结果 两组治疗后NHISS、CSS评分低于治疗前，且A组低于B组（P＜0.05）；两组治疗后PT、APTT、TT高于治疗前，且A组高于B组（P＜0.05）；两组治疗后MDA、IL-1β、TNF-α低于治疗前，且A组低于B组（P＜0.05）；A组不良反应发生率与B组比较，差异无统计学意义（P＞0.05）；A组mRS评分低于B组，MBI评分高于B组（P＜0.05）。结论 AIS发病3 h内给予阿替普酶溶栓治疗可获得理想效果，对患者神经功能、凝血功能、氧化及炎症反应均具有积极改善作用，且不增加不良反应。
Abstract:
Objective To study the effects of different alteplase thrombolysis time on neurological function and adverse reactions in patients with acute ischemic stroke (AIS).Methods A total of 90 patients with AIS admitted to Jiamusi Central Hospital from January 2019 to January 2022 were selected and divided into group A (45 cases) and group B (45 cases) according to the random number table method. Both groups were given intravenous thrombolysis with alteplase. The time of thrombolysis in group A was within 3 hours of onset, and that in group B was within 3-4.5 hours of onset. The neurological function [National Institutes of Health Stroke Scale (NHISS), Chinese Stroke Scale (CSS)], coagulation indexes [prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT)], oxidation and inflammatory response indexes [malondialdehyde (MDA), interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α)], adverse reactions and prognosis [modified Rankin Scale (mRS), modified Barthel index (MBI)] were compared between the two groups.Results After treatment, the scores of NHISS and CSS in the two groups were lower than those before treatment, and those in the group A were lower than the group B (P<0.05). After treatment, PT, APTT and TT in the two groups were higher than those before treatment, and those in the group A were higher than the group B(P<0.05). After treatment, MDA, IL-1β and TNF-α in the two groups were lower than those before treatment, and the group A was lower than the group B(P<0.05). There was no significant difference in the incidence of adverse reactions between group A and group B (P>0.05). The mRS score of group A was lower than that of group B, and the MBI score was higher than that of group B (P<0.05).Conclusion Thrombolytic therapy with alteplase within 3 hours of onset of AIS can achieve ideal results. It has a positive improvement effect on neurological function, coagulation function, oxidation and inflammatory response, and does not increase adverse reactions.

参考文献/References:

[1]鲁庆波,王雪梅,汪鸿浩,等.MR筛选下4.5～9 h缺血性脑卒中阿替普酶静脉溶栓联合标准Ⅱ级预防治疗的效果及安全性分析[J].中国医学装备,2021,18(6):64-67.[2]李小东,居靖,李令培,等.阿替普酶治疗急性缺血性脑卒中药物利用评价标准的建立与应用[J].中国药师,2021,24(7):323-326.[3]孟伟建,卢蕾,张宏博,等.阿替普酶静脉溶栓治疗急性缺血性脑卒中的临床研究[J].西北药学杂志,2021,36(2):279-282.[4]路俊芳.阿替普酶静脉溶栓治疗对急性脑梗死患者神经功能及生活质量的影响[J].中国药物与临床,2020,20(18):3114-3115.[5]林玉全,王升武,辜忠灵,等.急性缺血性脑卒中患者阿替普酶溶栓不同时间窗对血管再通率的影响[J].神经损伤与功能重建,2020,15(7):402-404.[6]Dorado L,Ahmed N,Thomalla G,et al.Intravenous Thrombolysis in Unknown-Onset Stroke: Results From the Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry[J].Stroke,2017,48(3):720-725.[7]中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志,2018,51(9):666-682.[8]赵洁,朴翔宇,吴悦.丁苯酞联合阿替普酶治疗急性缺血性脑卒中的临床效果及对患者血清炎性因子及神经递质水平的影响[J].中国医药,2019,14(4):553-557.[9]施学松.阿替普酶溶栓治疗对急性脑梗死患者氧化应激相关因子水平和神经功能的影响[J].卒中与神经疾病,2019,26(1):39-42.[10]王蕾,姜帅,何柳,等.急性缺血性脑卒中超早期阿替普酶静脉溶栓155例临床研究[J].中国药业,2017,26(21):35-38.[11]宋程光,刘长喜,曹群,等.阿替普酶静脉溶栓治疗急性轻型缺血性脑卒中的疗效分析[J].中国医科大学学报,2019,48(2):184-187.[12]陈苑,张怡,张敏,等.阿替普酶溶栓治疗对缺血性脑卒中患者凝血功能及血液流变学指标的影响[J].贵州医科大学学报,2019,44(11):1344-1348.[13]张黎宾,胡风云,佘晓岚.阿替普酶静脉溶栓治疗急性缺血性脑卒中患者疗效研究[J].中国药物与临床,2018,18(7):1088-1092.[14]高娟,高阳,刘顺达,等.阿替普酶静脉溶栓治疗轻、中度急性缺血性脑卒中的疗效[J].宁夏医科大学学报,2018,40(6):714-717.[15]杜怀文,洪芳,毕璐洁,等.阿替普酶静脉溶栓治疗急性缺血性脑卒中效果观察[J].中华实用诊断与治疗杂志,2018,32(3):287-290.[16]中国老年医学学会急诊医学分会,中华医学会急诊医学分会卒中学组,中国卒中学会急救医学分会. 急性缺血性脑卒中急诊急救中国专家共识(2018版)[J].中华急诊医学杂志,2018,27(7):721-728.[17]何元发,曹群,高红安.阿替普酶不同溶栓时间对急性缺血性脑卒中患者血清PRDX1 LPA的影响及疗效探究[J].河北医学,2019,25(1):127-131.[18]李旷怡,张英俭,蔡海荣,等.阿替普酶静脉溶栓治疗急性缺血性脑卒中的临床研究[J].中国临床神经科学,2017,25(5):564-566.[19]孟桃,刘骅,蒋萍,等.阿替普酶治疗急性缺血性脑卒中的疗效及预后影响因素分析[J].四川医学,2017,38(8):906-909.[20]潘成德,唐明山,邹耀兵,等.阿替普酶静脉溶栓治疗急性缺血性脑卒中疗效观察[J].海南医学,2017,28(8):1245-1247.[21]王自然,郑梅,赵广建,等.阿替普酶注射剂治疗急性缺血性脑卒中的临床研究[J].中国临床药理学杂志,2017,33(5):391-394.[22]吕志强,马立芝,朱战涛,等.阿替普酶静脉溶栓治疗急性缺血性脑卒中49例分析[J].中国急救复苏与灾害医学杂志,2017,12(12):1145-1147.[23]Mueller L,Pult F,Meisterernst J,et al.Impact of intravenous thrombolysis on recanalization rates in patients with stroke treated with bridging therapy[J].European Journal of Neurology,2017,24(8):1016-1021.

相似文献/References:

[1]王跃慧.急性缺血性脑卒中的药物治疗[J].医学信息,2022,35(11):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
　WANG Yue-hui.Drug Treatment of Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(14):44.[doi:10.3969/j.issn.1006-1959.2022.11.013]
[2]王 伟,宫秀群,余 亮.阿替普酶治疗急性脑梗死患者临床转归的影响因素[J].医学信息,2022,35(11):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
　WANG Wei,GONG Xiu-qun,YU Liang.The Influencing Factors of Clinical Outcome in Patients with Acute Cerebral Infarction Treated with Alteplase[J].Journal of Medical Information,2022,35(14):84.[doi:10.3969/j.issn.1006-1959.2022.11.022]
[3]褚春沐.阿加曲班联合阿替普酶静脉溶栓治疗急性脑梗死的效果及对脑血管储备功能的影响[J].医学信息,2022,35(13):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
　CHU Chun-mu.Effect of Argatroban Combined with Alteplase Intravenous Thrombolysis on Acute Cerebral Infarction and its Effect on Cerebrovascular Reserve Function[J].Journal of Medical Information,2022,35(14):133.[doi:10.3969/j.issn.1006-1959.2022.13.031]
[4]周 笳,董丽霞.阿替普酶联合华法林治疗慢阻肺合并肺栓塞的有效性分析[J].医学信息,2019,32(05):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
　ZHOU Jia,DONG Li-xia.Efficacy Analysis of Alteplase Combined with Warfarin in the Treatment of Chronic Obstructive Pulmonary Disease with Pulmonary Embolism[J].Journal of Medical Information,2019,32(14):146.[doi:10.3969/j.issn.1006-1959.2019.05.046]
[5]王珊珊.国内丁苯肽治疗急性缺血性脑卒中机制的应用研究[J].医学信息,2019,32(09):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
　WANG Shan-shan.Study on the Application of Domestic Butyl Phenyl Peptide in the Treatment of Acute Ischemic Stroke[J].Journal of Medical Information,2019,32(14):58.[doi:10.3969/j.issn.1006-1959.2019.09.019]
[6]郑钰蓉,殷 梅,罗 悯.急性缺血性脑卒中伴发脑心综合征的临床研究[J].医学信息,2022,35(17):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]
　ZHENG Yu-rong,YIN Mei,LUO Min.Clinical Study of Acute Ischemic Stroke with Cerebrocardiac Syndrome[J].Journal of Medical Information,2022,35(14):156.[doi:10.3969/j.issn.1006-1959.2022.17.043]
[7]于德爱,宋会伟.阿替普酶急诊溶栓治疗超早期急性心肌梗死的疗效[J].医学信息,2020,33(10):157.[doi:10.3969/j.issn.1006-1959.2020.10.047]
　YU De-ai,SONG Hui-wei.The efficacy of Alteplase in Emergency Thrombolysis for Ultra-early Acute Myocardial Infarction[J].Journal of Medical Information,2020,33(14):157.[doi:10.3969/j.issn.1006-1959.2020.10.047]
[8]赵东慧.阿替普酶静脉溶栓联合氯吡格雷对急性脑梗死患者脑血流动力学及CRP、Hcy、HDL-C水平的影响[J].医学信息,2022,35(20):74.[doi:10.3969/j.issn.1006-1959.2022.20.018]
　ZHAO Dong-hui.Effect of Alteplase Intravenous Thrombolysis Combined with Clopidogrel on Cerebral Hemodynamics and Levels of CRP, Hcy and HDL-C in Patients with Acute Cerebral Infarction[J].Journal of Medical Information,2022,35(14):74.[doi:10.3969/j.issn.1006-1959.2022.20.018]
[9]宋贵军.急性缺血性脑卒中静脉溶栓治疗[J].医学信息,2020,33(17):47.[doi:10.3969/j.issn.1006-1959.2020.17.014]
　SONG Gui-jun.Intravenous Thrombolytic Therapy for Acute Ischemic Stroke[J].Journal of Medical Information,2020,33(14):47.[doi:10.3969/j.issn.1006-1959.2020.17.014]
[10]褚春沐.血浆纤维蛋白原和D-二聚体在急性缺血性脑卒中治疗中的应用价值[J].医学信息,2022,35(21):101.[doi:10.3969/j.issn.1006-1959.2022.21.024]
　CHU Chun-mu.The Application Value of Plasma Fibrinogen and D-dimer in the Treatment of Acute Ischemic Stroke[J].Journal of Medical Information,2022,35(14):101.[doi:10.3969/j.issn.1006-1959.2022.21.024]

更新日期/Last Update: 1900-01-01